The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients
Objectives: To verify the effectiveness of G-CSF in the treatment of non-healing skin lesions in SSc patients. Methods: 26 SSc patients (23 F and 3 M, age 54 ±13,6 yrs) with skin ulcers were enrolled in a pilot study. Prior to the treatment with G-CSF, all ulcers failed to heal with conventional the...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-09-01
|
Series: | Reumatismo |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/246 |
id |
doaj-dccbddbf6d8c4c62bc304af39b73c955 |
---|---|
record_format |
Article |
spelling |
doaj-dccbddbf6d8c4c62bc304af39b73c9552020-11-24T21:06:04ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-09-01581263010.4081/reumatismo.2006.26The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patientsAndrea CarusoUmberto FranciosiMichele ColaciRocco MagistroDilia GiuggioliClodoveo FerriObjectives: To verify the effectiveness of G-CSF in the treatment of non-healing skin lesions in SSc patients. Methods: 26 SSc patients (23 F and 3 M, age 54 ±13,6 yrs) with skin ulcers were enrolled in a pilot study. Prior to the treatment with G-CSF, all ulcers failed to heal with conventional therapies carried out for a period of 1-5 years. All patients were treated with 5μg/kg G-CSF subcutaneously for 5 days. Healing time, quality of wounds, VAS and HAQ-DI were used to evaluate the efficacy of the treatment. Results: An improvement of skin ulcers was observed in 24/26 patients; in particular, 22/26 wounds completely healed, 2/26 showed a partial healing, in only 2 patients skin ulcers did not change during the 6-month follow-up. The quality of life improves as showed by VAS (from 88±13 to 55±28; p<.0001) and HAQ (from 2.12 ±0.45 to 1.28±0.30; p<.0001). The eradication of pathogens from the infected ulcers was also observed in 12/12 patients; while no adverse side effects related to G-CSF were recorded. Our study suggests that G-CSF may be usefully employed in scleroderma skin ulcers refractory to conventional treatments.http://www.reumatismo.org/index.php/reuma/article/view/246 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andrea Caruso Umberto Franciosi Michele Colaci Rocco Magistro Dilia Giuggioli Clodoveo Ferri |
spellingShingle |
Andrea Caruso Umberto Franciosi Michele Colaci Rocco Magistro Dilia Giuggioli Clodoveo Ferri The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients Reumatismo |
author_facet |
Andrea Caruso Umberto Franciosi Michele Colaci Rocco Magistro Dilia Giuggioli Clodoveo Ferri |
author_sort |
Andrea Caruso |
title |
The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients |
title_short |
The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients |
title_full |
The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients |
title_fullStr |
The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients |
title_full_unstemmed |
The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients |
title_sort |
treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (g-csf) in 26 patients |
publisher |
PAGEPress Publications |
series |
Reumatismo |
issn |
0048-7449 2240-2683 |
publishDate |
2011-09-01 |
description |
Objectives: To verify the effectiveness of G-CSF in the treatment of non-healing skin lesions in SSc patients. Methods: 26 SSc patients (23 F and 3 M, age 54 ±13,6 yrs) with skin ulcers were enrolled in a pilot study. Prior to the treatment with G-CSF, all ulcers failed to heal with conventional therapies carried out for a period of 1-5 years. All patients were treated with 5μg/kg G-CSF subcutaneously for 5 days. Healing time, quality of wounds, VAS and HAQ-DI were used to evaluate the efficacy of the treatment. Results: An improvement of skin ulcers was observed in 24/26 patients; in particular, 22/26 wounds completely healed, 2/26 showed a partial healing, in only 2 patients skin ulcers did not change during the 6-month follow-up. The quality of life improves as showed by VAS (from 88±13 to 55±28; p<.0001) and HAQ (from 2.12 ±0.45 to 1.28±0.30; p<.0001). The eradication of pathogens from the infected ulcers was also observed in 12/12 patients; while no adverse side effects related to G-CSF were recorded. Our study suggests that G-CSF may be usefully employed in scleroderma skin ulcers refractory to conventional treatments. |
url |
http://www.reumatismo.org/index.php/reuma/article/view/246 |
work_keys_str_mv |
AT andreacaruso thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT umbertofranciosi thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT michelecolaci thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT roccomagistro thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT diliagiuggioli thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT clodoveoferri thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT andreacaruso treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT umbertofranciosi treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT michelecolaci treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT roccomagistro treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT diliagiuggioli treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients AT clodoveoferri treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients |
_version_ |
1716766882999042048 |